Advanced searches left 3/3

Diabetic Macular Edema - Europe PMC

Summarized by Plex Scholar
Last Updated: 02 September 2022

* If you want to update the article please login/register

Optical coherence tomography angiography analysis of changes in the foveal avascular zone in eyes with diabetic macular edema treated with intravitreal anti-vascular endothelial growth factor.

Background: Objective Objectives to investigate the changes in foveal avascular zone area, perimeter, and circularity in the superficial and deep capillary plexuses of diabetic macular edema treated with intravitreal anti-VEGF using optical coherence tomography angiography. Methods This prospective observational review included 56 eyes from 32 patients with DME who had intravitreal anti-VEGF. Results The mean number of intravitreal anti-VEGF injections received during the observation period was 4. 60 u00b1 0. 82 u00b1. 82 mm. Despite having no change in the FAZ parameters, there was nevertheless a statistically significant decrease in CST as well as a statistically significant rise in BCVA during the observation period. Conclusions emergence in eyes with DME was found in the FAZ area, perimeter, and circularity in the SCP and DCP as measured by OCTA during the first 6 months of intravitreal anti-VEGF therapy in eyes with DME.

Source link: https://europepmc.org/article/MED/36028899


Faricimab for Treatment-Resistant Diabetic Macular Edema.

Objectives: The goal of this review was to assess the short-term outcomes in treatment-resistant diabetic macular edema patients, who went from intravitreal aflibercept to intravitreal faricimab. Methods The empirical review was conducted on DME people receiving IVA therapy at a single private facility in a single private clinic. Patients were switched to IVF and underwent three injections within four months, while control patients stayed on IVA for the same period and received three injections within four months. At the end of the 4-month investigation, there were 37. 5% in the study group and 37. 7% in the control group, who had a CMT of less than 300 mm without retinal fluid on OCT at the end of the research. At the end of the 4-month study, there were 41. 7% in the study group and 11. 1% in the control group, who had two or more lines of visual acuity at the same time.

Source link: https://europepmc.org/article/MED/36042912


Aflibercept versus Faricimab in the Treatment of Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Review.

Both diabetic macular edema and neovascular age-related macular degeneration are common retinal disorders that account for the majority of blindness in the working-age and older population of industrial countries. Faricimab is the first monoclonal antibody for intravitreal use that can neutralize VEGF and Ang-2. Faricimab's prolonged service has increased the time between successive injections in nAMD and DME patients up to three or four months, proving a major benefit for patients and an alternative to implanted drug delivery systems.

Source link: https://europepmc.org/article/MED/36012690


Clinical Characteristics and Long-Term Outcomes in Diabetic Macular Edema Patients: With/ Without Additional injection Following Ranibizumab Loading.

Purpose: According to the need for additional therapies after intravitreal ranibizumab loading injections, the primary aim of this study was to examine baseline characteristics in patients with diabetic macular edema during 7 years. DME's intravitreal RBZ loadings for DME for the first time for seven years were examined, as well as the clinical records of 32 patients treated with intravitreal RBZ loadings for DME during 7 years. Following three monthly RBZ injections, additional treatment was ordered based on the patient's reaction to RBZ loading. In the NA group than in the Add group, Baseline MV was much smaller than in the Add group. Patients with serous retinal detachment or cystic macular edema in the No add group were significantly lower in the No add group than in the Add group. Conclusions DME patients without additional medications after 7 years after the initial loading treatment had shorter duration of DME and DRT morphologic type, lower MV at baseline, and improved long-term visual prognosis.

Source link: https://europepmc.org/article/MED/35989066


Subthreshold Laser Treatment for Non-Center Involved Diabetic Macular Edema via Non-Damaging Retinal Laser Therapy (NRT)

Background:/Objectives Objectives: In patients with non-center involvement diabetic macular edema, the subthreshold laser therapy by NRT can be used to determine the safety of subthreshold laser therapy using NRT. Methods: In this prospective controlled trial, NRT with 577 nm wavelength was applied to the edematous inner subfields as required at 3 monthly intervals, while the control group received no medical attention. During the first and second years, CI-DME growth rates that required intravitreal anti-VEGF therapy were not different between the first and second years. In any eye on fundus autofluorescence imaging, no laser scar was found.

Source link: https://europepmc.org/article/PPR/PPR532887


Artificial intelligence in screening, diagnosis, and classification of diabetic macular edema: A systematic review.

Using retinal imaging technologies such as optical coherence tomography and color fundus photography, we provide an overview of the current state of various AI techniques for DME screening, diagnosis, and classification. Deep learning models have the capability to produce an accurate and cost-effective method for DME screening and diagnosis based on our findings. The use of decision support systems and applications based on AI in processing retinal images provided by OCT and CFP enhances the sensitivity and specificity in DME screening and detection.

Source link: https://europepmc.org/article/MED/35970233


The impact of the vitreomacular interface on functional and anatomical outcomes in diabetic macular edema treated with three different anti-VEGF agents: post hoc analysis of the Protocol T study.

Scope: Background: To determine the effects of baseline vitreomacular interface status on treatment outcomes in patients treated with three different anti-vascular endothelial growth factors for diabetic macular edema, we need to investigate the effects of baseline vitreomacular interface status. Following the 12 months follow-up, complete adhesion eyes gained on average +3. 7 more ETDRS letters relative to the complete PVD group at the end of the 12 months follow-up. VMI status influences functional outcomes in DME patients treated with anti-VEGF injections, according to this review. Complete or partial VMA at baseline could be associated with a greater treatment benefit than those with complete PVD.

Source link: https://europepmc.org/article/MED/35962998


Changes of Estimated Glomerular Filtration Rate and Glycated Hemoglobin A1c in Diabetic Macular Edema Patients Treated by Ranibizumab and Aflibercept in the Tertiary Referral Hospital.

Introduction and Objectives: vascular endothelial growth factor inhibitors injections are the first-indicated treatments for diabetic macular edema. Our study aims to determine trends in glycated hemoglobin A1c and estimated glomerular filtration rate in patients treated with IVI ranibizumab and aflibercept therapy, as well as patients who have not received IVI drugs. In the China Medical University Hospital-Clinical Research Data Repository, there were 17,165 DME patients with documented ophthalmology visits. HbA1c and eGFR at baseline and 3 and 12 months after the index date between the two groups was determined. Results : eGFR decreased with age and time, and was not related to IVI anti-VEGF therapy in our tertiary referral hospital, according to this report. IVI anti-VEGF therapy was also linked to improved HbA1c control, as well as improved HbA1c monitoring. DME patients can be given intravitreal VEGF inhibitors without causing any renal impairment, according to DME.

Source link: https://europepmc.org/article/MED/36013548


Glycemic Control after Initiation of Anti-VEGF Treatment for Diabetic Macular Edema.

Based on a questionnaire and changes in hemoglobin A1c, we will investigate the impact on glycemic control after beginning VEGF therapy for DME. We conducted a retrospective multicenter study evaluating 112 patients with DME who underwent anti-VEGF treatment and their HbA1c changes in two years. After 18 months in patients who said that anti-VEGF medications were expensive, HbA1c was significantly lower after 18 months. The introduction of anti-VEGF therapy for DME has an effect on HbA1c levels in relation to more aggressive glycemic control.

Source link: https://europepmc.org/article/MED/36012896


The Efficacy and Safety of Dexamethasone Intravitreal Implant for Diabetic Macular Edema and Macular Edema Secondary to Retinal Vein Occlusion: A Meta-Analysis of Randomized Controlled Trials.

Purpose The aim of this meta-analysis was to determine the effectiveness and safety of dexamethasone intravitreal implant for the treatment of diabetic macular edema secondary to macular edema. Conclusions The DEX treatment of RVO-ME was associated with an improvement in best corrected visual acuity and central retinal thickness, according to the study. DME treatment by DEX was more effective than anti-VEGF in terms of CRT reduction, with CRT reductions in that regard. The risk of cataract formation from RVO-ME and the presence of high intraocular pressure in high-introcular pressure was significantly higher with DEX than with anti-VEGF therapy, according to a safety analysis. With DEX, the risk of cataracts from DME was much greater than with anti-VEGF therapy. With DEX, the risk of elevated IOP was significantly higher than with anti-VEGF therapy. Conclusions DEX was more effective and slightly less safe than anti-VEGF therapy in patients with DME and RVO-ME.

Source link: https://europepmc.org/article/MED/35982771

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions